Mutational analysis of the mitochondrial tRNA genes and flanking regions in umbilical cord tissue from uninfected infants receiving AZT-based therapies for prophylaxis of HIV-1

Environmental and Molecular Mutagenesis

Volumn 50, Issue 1, 2009, Pages 10-26

  Torres, Salina M ^a   Walker, Dale M ^a,b   McCash, Consuelo L ^a   Carter, Meghan M ^a   Ming, Jessica ^a   Cordova, Edmund M ^a   Pons, Rachel M ^a   Cook Jr , Dennis L ^a   Seilkop, Steven K ^c   Copeland, William C ^d   Walker, Vernon E ^a,b  

^a LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^b BioMosaics Incorporated   (United States)

^c SKS Consulting Services   (United States)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

3TC; Antiretrovirals; AZT; DGGE; Mitochondrial DNA mutation; Nucleoside analogs; Transplacental exposure; tRNA genes

Indexed keywords

LAMIVUDINE; MITOCHONDRIAL DNA; TRANSFER RNA; ZIDOVUDINE;

ARTICLE; CONTROLLED STUDY; DENATURING GRADIENT GEL ELECTROPHORESIS; DNA FLANKING REGION; DNA POLYMORPHISM; FEMALE; GENE MUTATION; GENE SEQUENCE; HETEROPLASMY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN TISSUE; INFANT; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NEWBORN; PATHOGENICITY; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; UMBILICAL CORD;

BASE SEQUENCE; CASE-CONTROL STUDIES; DNA PRIMERS; DNA, MITOCHONDRIAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; INFANT; LAMIVUDINE; MUTATION; POLYMORPHISM, GENETIC; REVERSE TRANSCRIPTASE INHIBITORS; RNA, TRANSFER; UMBILICAL CORD; ZIDOVUDINE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 58549094952     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.20433     Document Type: Article

References (105)

1. Bai R-K, Leal SM, Covarrubias D, Liu A, Wong L-JC. 2007. Mitochondrial genetic background modifies breast cancer risk. Cancer Res 67:4687-4694.
2. Barret B, Tardieu M, Rustin P, Lacroix C, Chabrol B, Desguerre I, Dollfus C, Mayaux MJ, Blanche S. 2003. Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: Clinical screening in a large prospective cohort. AIDS 17: 1769-1785.
3. Benhammou V, Tardieu M, Warszawski J, Rustin P, Blanche S. 2007. Clinical mitochondrial dysfunction in uninfected children born to HIV-infected mothers following perinatal exposure to nucleoside analogues. Environ Mol Mutagen 48:173-179.
4. Benson DA, Karsch-Mizrachi I, Lopman DJ, Ostell J, Rapp BA, Wheeler DL. 2000. Nucleic Acids Res 28:15-18.
5. Bialkowska A, Bialkowski K, Gerschenson M, Diwan BA, Jones AB, Olivero OA, Poirier MC, Anderson LM, Kasprzak KS, Sipowicz MA. 2000. Oxidative DNA damage in fetal tissues after transplacental exposure to 3′-azido- 3′-deoxythymidine (AZT). Carcinogenesis 21:1059-1062.
6. Blanche S, Tardieu M, Rustin P, Slama A, Barret B, Firtion G, Ciraru Vigneron N, Lacroix C, Rouzioux C, Mandelbrot L, Desguerre I, Rotig A, Mayaux MJ, Delfraissy JF. 1999. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 354:1084-1089.
7. Blanche S, Tardieu M, Benhammou V, Warszawski J, Rustin P. 2006. Mitochondrial dysfunction following perinatal exposure to nucleoside analogues. AIDS 20:1685-1690.
8. Boles RG, Chaudhari D, Soderkvist J, Podberezin M, Ito M. 2003. Quantification of mitochondrial DNA heteroplasmy by temporal temperature gradient gel electrophoresis. Clin Chem 49:198-200.
9. Brandon M, Baldi P, Wallace DC. 2006. Mitochondrial mutations in cancer. Oncogene 25:4647-4662.
10. Brinkman K, ter Hofstede JM, Burger DM, Smeitink JAM, Koopmans PP. 1998. Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway. AIDS 12:1735-1744.
11. Brogly SB, Ylitalo N, Mofenson LM, Oleske J, Van Dyke R, Crain MJ, Abzug MJ, Brady M, Jean Phillipe P, Hughes D, Seage GR III. 2007. In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-unin-fected children. AIDS 21:929-938.
12. Brown MD, Torroni A, Shoffner JM, Wallace DC. 1992. Mitochondrial tRNA(Thr) mutations and lethal infantile mitochondrial myopathy. Am J Hum Genet 51:446-447.
13. Canter JA, Kallianpur AR, Parl FF, Millikan RC. 2005. Mitochondrial DNA G10398A polymorphism and invasive breast cancer in African-American women. Cancer Res 65:8028-8033.
14. Cariello NF, Keohavong P, Kat AG, Thilly WG. 1990. Molecular analysis of complex human cell populations: Mutational spectra of MNNG and ICR-191. Mutat Res 231:165-176.
15. Carter MM, Torres SM, Cook DL Jr, McCash CL, Yu M, Griegos J, Walker DM, Walker VE. 2007. Relative mutagenic potencies of several nucleoside reverse transcriptase inhibitors at the HPRT and TK loci of exposed human TK6 lymphoblastoid cells. Environ Mol Mutagen 48:239-247.
16. Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, Hayani K, Handelsman E, Smeriglio V, Hoff R, Blattner W. 2002. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 29:484-494.
17. Cooper ER, DiMauro S, Sullivan M, Jones-Evans D, Kay L, Moloney C, Regan AM. 2004.Biopsy-confirmed mitochondrial dysfunction in an HIV-exposed infant whose mother received combination anti-retrovirals during the last 6 weeks of pregnancy. 15th International AIDS Conference Bangkok. 11-16 July, Bankok, Thailand. Abstract TuPeB4394.
18. Dagan T, Sable C, Bray J, Gerschenson M. 2002. Mitochondrial dysfunction and antiretroviral nucleoside analog toxicities: What is the evidence? Mitochondrion 1:397-412.
19. Divi RL, Walker VE, Wade NA, Nagashima K, Seilkop SK, Adams ME, Nesel CJ, O'Neill JP, Abrams EJ, Poirier MC. 2004. Mitochondrial damage and DNA depletion in cord blood and umbilical cord from infants exposed in utero to Combivir. AIDS 18:1013-1021.
20. Divi RL, Leonard SL, Kuo MM, Walker BL, Orozco CC, St. Claire MC, Nagashima K, Harbaugh SW, Harbaugh JW, Thamire C, Sable CA, Poirier MC. 2005. Cardiac mitochondrial compromise in 1-yr-old Erythrocebus patas monkeys perinatally-exposed to nucleoside reverse transcriptase inhibitors. Cardiovasc Toxicol 5:333-346.
21. Divi RL,LeonardSL,KuoMM,NagashimaK,ThamireC,St. Claire MC, Wade NA, Walker VE, Poirier MC. 2007. Transplacentally exposed human and monkey newborn infants show similar evidence of nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity. Environ Mol Mutagen 47:201-209.
22. Dorenbaum A, Cunningham CK, Gelber RD, Culnane M, Mofenson L, Britto P, Rekacewicz C, Newell ML, Delfraissy JF, Cunningham-Schrader B, Mirochnick M, Sullivan JL;International PACTG 316 Team. 2002. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA 288:189-198.
23. Escobar P, Olivero OA, Day B, Wade NA, Abrams EJ, Nesel CJ, Ness RB, Day RD, Day BW, Meng Q, O'Neill JP, Walker DM, Poirier MC, Walker VE, Bigbee WL; for the study team. 2007. Genotox-icity assessed by the Comet and GPA assays following in vitro exposure of human lymphoblastoid cells (H9) or perinatal exposure of mother-child pairs to AZT or AZT-3TC. Environ Mol Mutagen 48:330-343.
24. European Collaborative Study. 2003. Exposure to antiretroviral therapy in utero or early life: The health of uninfected children born to HIV-infected women. J Acquir Immune Defic Syndr 32:380-387.
25. European Collaborative Study. 2005. Mother to child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 40:458-465.
26. Eyden BP, Ponting J, Davies H, Bartley C, Torgersen E. 1994. Defining the myofibroblast: Normal tissues, with special reference to the stromal cells of Wharton's jelly in human umbilical cord. J Sub-microsc Cytol Pathol 26:347-355.
27. Foster C, Lyall H. 2008. HIV and mitochondrial toxicity in children. J Antimicrob Chemother 61:8-12.
28. Funk MJ, Belinson SE, Pimenta JM, Morsheimer M, Gibbons DC. 2007. Mitochondrial disorders among infants exposed to HIV and anti-retroviral therapy. Drug Safety 30:845-859.
29. Harihara S, Hirai M, Suutou Y, Shimizu K, Omoto K. 1992. Frequency of a 9-bp deletion in the mitochondrial DNA among Asian populations. Hum Biol 64:161-166.
30. Hashiguchi K, Bohr VA, de Souza-Pinto NC. 2004. Oxidative stress and mitochondrial DNA repair: implications for NRTIs induced DNA damage. Mitochondrion 4:215-222.
31. Helm M, Brule H, Friede D, Giege R, Putz D, Florentz C. 2000. Search for characteristic structural features of mammalian mitochondrial tRNAs. RNA 6:1356-1379.
32. Hertzberg M, Mickleson KN, Serjeantson SW, Prior JF, Trent RJ. 1989. An Asian-specific 9-bp deletion of mitochondrial DNA is frequently found in Polynesians. Am J Hum Genet 44:504-510.
33. Hong H-H, Dunnick J, Herbert R, Devereux TR, Kim Y, Sills RC. 2007. Genetic alterations in K-ras and p53 cancer genes in lung neoplasms of Swiss (CD-1) male mice following AZT transplacental exposure. Environ Mol Mutagen 48:299-306.
34. IARC. 2000. General remarks; and the Monograph on Zidovudine. IARC Monographs on the evaluation of carcinogenic risks to humans, some antiviral and antineoplastic drugs, and pharmaceutical agents.IARC Scientific Publications No. 76, Lyon, pp 35-12 and 73-127.
35. Kajander OA, Kunnas TA, Perola M, Lehtinen SK, Karhunen PJ, Jacobs HT. 1999. Long-extension PCR to detect deleted mitochondrial DNA molecules is compromized by technical artefacts. Biochem Biophys Res Commun 254:507-514.
36. Kakuda TM. 2000. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 22:685-708.
37. Kallings LO. 2008. The first postmodern pandemic: 25 years of HIV/AIDS. J Intern Med 263:218-243.
38. Kelley SO, Steinberg SV, Schimmer P. 2000. Functional defects of pathogenic human mitochondrial tRNAs related to structural fragility. Nat Struct Biol 7:862-865.
39. Kohler JJ, Lewis W. 2007. A brief overview of mechanisms of mitochondrial toxicity from NRTIs. Environ Mol Mutagen 48:166-172.
40. Kondrashov FA. 2005. Prediction of pathogenic mutations in mitochondrially encoded human tRNAs. Hum Mol Genet 14:2415-2419.
41. Lerman LS, Silverstein K. 1987. Computational simulation of DNA melting and its application to denaturing gradient gel electrophoresis. Methods Enzymol 155:482-501.
42. Levinger L, Morl M, Florentz C. 2004. Mitochondrial tRNA 3′ end metabolism and human disease. Nucleic Acids Res 32:5430-5441.
43. Lewis W. 2003. Mitochondrial dysfunction and nucleoside reverse transcriptase inhibitor therapy: Experimental clarifications and persistent clinical questions. Antiviral Res 58:189-197.
44. Lewis W. 2004. Cardiomyopathy, nucleoside reverse transcriptase inhibitors and mitochondria are linked through AIDS and its therapy. Mitochondrion 4:141-152.
45. Lewis W. 2005. Nucleoside reverse transcriptase inhibitors, mitochondrial DNA, AIDS therapy. Antivir Ther 10(Suppl 2): M13-M27.
46. Lewis W, Dalakas MC. 1995. Mitochondrial toxicity of antiviral drugs. Nat Med 1:417-422.
47. Lewis W, Day BJ, Copeland WC. 2003. Mitochondrial toxicity of NRTI antiviral drugs: An integrated cellular perspective. Nat Rev Drug Discov 2:812-822.
48. Lim SE, Copeland WC. 2001. Differential incorporation and removal of antiviral deoxynucleotides by human DNA polymerase gamma. J Biol Chem 276:23616-23623.
49. Lindegren ML, Rhodes P, Gordon L, Fleming P. 2000. Drug safety during pregnancy and in infants. Lack of mortality related to mitochondrial dysfunction among perinatally HIV-exposed children in pediatric HIV surveillance. Ann N Y Acad Sci 918:222-235.
50. Lipshultz SE. 2008. The effect of ART exposure during childhood on cardiovascular structure and function in children born to HIV infected mothers. Toxicologist 102(Number 1):481.
51. Lipshultz SE, Easley KA, Orav EJ, Kaplan S, Starc TJ, Bricker JT, Lai WW, Moodie DS, Sopko G, McIntosh K, Colan SD. 2000. Absence of cardiac toxicity of zidovudine in infants. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection Study Group. N Engl J Med 343:759-766.
52. 2 HIV): A cohort study. Lancet 360:368-373.
53. Lipshultz SE, Shearer WT, Rich T, Thompson B, Cheng I, Harmon T, Orav EJ, Pignatelli RH, Bezold LI, LaRussa P, Starc TJ, Glickstein J, O'Brian S, McIntosh K, Cooper ER, Coaln SD. 2005. Antiretroviral therapy (ART)-associated cardiotoxicity in uninfected but ART-exposed infants born to HIV-infected women: The prospective NHLBI CHAART-1 study. Mutat Res 577(Suppl 1):e28.
54. Lipshultz SE, Shearer WT, Thompson B, Rich K, Cheng I, Milton A, Orav EJ, Pignatelli RH, Bezold LI, LaRussa P, Starc TJ, Glick-stein J, McIntosh K, Cooper ER, O'Brien S, Colan SD. 2006.Antiretroviral therapy (ART)-associated cardiotoxicity in uninfected and ART-exposed infants born to HIV-infected women: The prospective NHLBI CHAART-I Study. Late-Breaker Abstract # 8, Proceedings of 2006 Pediatric Academic Societies Annual Meeting, San Francisco, CA.
55. Lorenz JG, Smith DG. 1994. Distribution of the 9-bp mitochondrial DNA region V deletion among North American Indians. Hum Biol 66:777-788.
56. Lynx MD, McKee EE. 2006. 3′-Azido-3′-deoxythymidine (AZT) is a competitive inhibitor of thymidine phosphorylation in isolated rat heart and liver mitochondria. Biochem Pharmacol 72:239-243.
57. Maagard A, Holberg-Petersen M, Kollberg G, Oldfors A, Sandvik L, Brun JN. 2006. Mitochondrial (mt)DNA changes in tissue may not be reflected by depletion of mtDNA in peripheral blood mononuclear cells in HIV-infected patients. Antivir Ther 11:601-608.
58. Martin AM, Hammond E, Nolan D, Pace C, Den Boer M, Taylor L, Moore H, Martinez OP, Christiansen FT, Mallal S. 2003. Accumulation of mitochondrial DNA mutations in human immunodeficiency virus-infected patients treated with nucleoside-analogue reverse-transcriptase inhibitors. Am J Hum Genet 72:549-560.
59. McComsey G, Tan DJ, Lederman M, Wilson E, Wong LJ. 2002. Analysis of the mitochondrial DNA genome in the peripheral blood leukocytes of HIV-infected patients with or without lipoatrophy. AIDS 16:513-518.
60. McComsey G, Bai RK, Maa JF, Seekins D, Wong LJ. 2005. Extensive investigations of mitochondrial DNA genome in treated HIV-infected subjects: Beyond mitochondrial DNA depletion. J Acquir Immune Defic Syndr 39:181-188.
61. McFarland R, Elson JL, Taylor RW, Howell N, Turnbull DM. 2004. Assigning pathogenicity to mitochondrial tRNA mutations: When ''definitely maybe'' is not good enough. Trends Genet 20:591-596.
62. Meng Q, Olivero OA, Fasco MJ, Bellisario R, Kaminsky LS, Pass KA, Abrams EJ, Wade NA, Poirier MC, Walker VE, protocol team. 2007. Plasma and cellular markers of 3′-azido-3′-dideoxythymi-dine (AZT) metabolism as indicators of DNA damage in cord blood mononuclear cells from infants receiving prepartum NRTIs. Environ Mol Mutagen 48:307-321.
63. Michikawa Y, Hofhaus G, Lerman LS, Attardi G. 1997. Comprehensive, rapid and sensitive detection of sequence variants of human mitochondrial tRNA genes. Nucleic Acids Res 25:2455-2463.
64. Minkoff H, Ahdieh L, Watts DF, Greenblatt RM, Schmidt J, Schneider M, Stek A. 2001. The relationship of pregnancy to the use of highly active antiretroviral therapy. Am J Obstet Gynecol 184:1221-1227.
65. Miró Ò,Gómez M, Pedrol E, Cardellac F, Nunes V, Casadamont J. 2000. Respiratory chain dysfunction associated with multiple mitochondrial DNA deletions in antiretroviral therapy-related lipodystrophy. AIDS 14:1855-1857.
66. Moyle G. 2000. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin Ther 22:911-936; discussion 898.
67. Myers RM, Fischer SG, Maniatis T, Lerman LS. 1985. Modification of the melting properties of duplex DNA by attachment of a GC-rich DNA sequence as determined by denaturing gradient gel electrophoresis. Nucleic Acids Res 13:3111-3129.
68. Noguera A, Fortuny C, Munoz-Almagro C, Sanchez E, Vilaseca MA, Artuch R, Pou J, Jimenez R. 2004. Hyperlactatemia in human immunodeficiency virus-uninfected infants who are exposed to anti-retrovirals. Pediatrics114598-114603.
69. Olivero OA, Anderson LM, Diwan BA, Haines DC, Harbaugh SW, Mos-kal TJ, Jones AB, Rice JM, Riggs CW, Logsdon D, Yuspa SH, Poirier MC. 1997. Transplacental effects of 3′-azido-2′,3′-dideox-ythymidine (AZT): Tumorigenicity in mice and genotoxicity in mice and monkeys. J Natl Cancer Inst 89:1602-1608.
70. Olivero OA, Shearer GM, Chougnet CA, Kovacs AA, Landay AL, Baker R, Stek AM, Khoury MM, Proia LA, Kessler HA, Sha BE, Tarone RE, Poirier MC. 1999. Incorporation of zidovudine into leukocyte DNA from HIV-1-positive adults and pregnant women, and cord blood from infants exposed in utero. AIDS 13: 919-925.
71. Olivero OA, Shearer GM, Chougnet CA, Kovacs AA, Baker R, Stek AM, Khoury MM, Poirier MC. 2000. Incorporation of zidovudine into cord blood DNA of infants and peripheral blood DNA of their HIV-1-positive mothers. Ann N Y Acad Sci 918:262-268.
72. Olivero OA, Fernandez JJ, Antiochos BB, Wagner JL, St. Claire ME, Poirier MC. 2002. Transplacental genotoxicity of combined anti-retroviral nucleoside analogue therapy in Erythrocebus patas monkeys. J Acquir Immune Defic Syndr 29:323-329.
73. O'Neill JP, Gundel RM, Trombley LM, Walker VE. 2001. HPRT mutant frequency and mutation spectra in newborns with perinatal exposure to antiviral drugs. Environ Mol Mutagen 37(Suppl 32):58.
74. Ozawa T, Ito T, Deguchi H, Kawamura K. 1991. Patients with idiopathic cardiomyopathy belong to the same mitochondrial DNA gene family of Parkinson's disease and mitochondrial encephalomyop-athy. Biochem Biophys Res Commun 177:518-525.
75. Perinatal Safety Review Working Group. 2000. Nucleoside exposure in children of HIV-infected women receiving antiretroviral drugs: Absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States Cohorts. J Acquir Immune Defic Syndr 25:261-268.
76. Poirier MC, Divi RL, Al-Harthi L, Olivero OA, Nguyen V, Walker B, Landay AL, Walker VE, Charurat M, Blattner WA. 2003. Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. J Acquir Immune Defic Syndr 33:175-183.
77. Poirier MC, Olivero OA, Walker DM, Walker VE. 2004. Perinatal geno-toxicity and carcinogenicity of the antiretroviral nucleoside analog drugs. Toxicol Appl Pharmacol 199:151-161.
78. Powderly WG. 2002. Long-term exposure to lifelong therapies. J Acquir Immune Defic Syndr 29(Suppl 1):S28-S40.
79. Ruiz-Pesini E, Lott MT, Procaccio V, Poole J, Brandon MC, Mishmar D, Yi C, Kreuziger J, Baldi P, Wallace DC. 2007. An enhanced MITOMAP with a global mtDNA mutational phylogeny. Nucleic Acids Res 35 (Database issue):D823-D828. URL: http://www.mitomap.org.
80. Rupert V, Nolte D, Aschenbrenner T, Pankuweit S, Funck R, Maisch F. 2004. Novel point mutations in the mitochondrial DNA detected with dilated cardiomyopathy by screening the whole mitochondrial genome. Biochem Biophys Res Commun 318:535-543.
81. Saxena R, de Bakker PI, Singer K, Mootha V, Burtt N, Hirschhorn JN, Gaudet D, Isomaa B, Daly MJ, Groop L, Ardlie KG, Altshuler D. 2006. Comprehensive association testing of common mitochondrial DNA variation in metabolic disease. Am J Hum Genet 79:54-61.
82. Sexton AJ, Turmaine M, Cai WQ, Burnstock G. 1996. A study of the ultrastructure of developing human umbilical cord vessels. J Anat 188:75-85.
83. Shiramizu B, Shikuma KM, Kamemoto L, Gerschenson M, Erdem G, Pinti M, Cossarizza A, Shikuma C. 2003. Placenta and cord blood mitochondrial DNA toxicity in HIV-infected women receiving nucleoside reverse transcriptase inhibitors during pregnancy. J Acquir Immune Defic Syndr 32:370-374.
84. Sobolewski K, Bañkowski E, Chyczewski L, Jaworski S. 1997. Collagen and glycosaminoglycans of Wharton's jelly. Biol Neonate 71:11-21.
85. Song S, Pursell ZT, Copeland WC, Longley MJ, Kukel TA, Mathews CK. 2005. DNA precursor asymmetries in mammalian tissue mitochondria and possible contribution to mutagenesis through reduced replication fidelity. Proc Natl Acad Sci USA 102:4990-4995.
86. Spector SA, Saitoh A. 2006. Mitochondrial dysfunction: Prevention of HIV-1 mother-to-infant transmission outweighs fear. AIDS 20:1777-1778.
87. Susan-Resiga D, Bentley AT, Lynx MD, LaClair DD, McKee EE. 2007. Zidovudine inhibits thymidine phosphorylation in isolated perfused rat heart. Antimicrob Agents Chemother 51: 1142-1149.
88. Takechi K, Kuwabara Y, Mizuno M. 1993. Ultrastructural and immuno-histochemical studies of Wharton's jelly umbilical cord cells. Placenta 14:235-245.
89. Thorne C, Newell ML. 2007. Safety of agents used to prevent mother-to-child transmission of HIV: Is there any cause for concern? Drug Safety 30:203-213.
90. Torpey JL. 2007. Developing a DNA microarray for human ancestry and migration. Honors Thesis. Department of Chemistry. Medford, MA: Tufts University.
91. Torres SM, Walker DM, Carter MM, Cook DL Jr, McCash CL, Cordova EM, Olivero OA, Poirier MC, Walker VE. 2007. Cytoxicity and mutagenicity of zidovudine, Lamivudine, and abacavir following in vitro exposure of human lymphoblastoid cells or in utero exposure of CD-1 mice to single agents or drug combinations. Environ Mol Mutagen 48:224-238.
92. Torroni A, Petrozzi M, Santolamazza P, Sellitto D, Cruciani F, Scozzari R. 1995. About the "Asian"-specific 9-bp deletion of mtDNA. Am J Hum Genet 57:507-508.
93. Tovo PA, Chiapello N, Gabiano C, Zeviani M, Spada M. 2005. Zidovudine administration during pregnancy and mitochondrial disease in the offspring. Antivir Ther 10:697-699.
94. Venhoff N, Walker UA. 2006. Mitochondrial disease in the offspring as a result of antiretroviral therapy. Expert Opin Drug Saf 5:373-381.
95. Walker DM, Poirier MC, Campen MJ, Cook DL Jr, Divi RL, Nagashima K, Lund AK, Cossey PY, Hahn FF, Walker VE. 2004. Persistence of mitochondrial toxicity in hearts of female B6C3F1 mice exposed in utero to 3′-azido-3′- deoxythymidine. Cardiovasc Toxicol 4:133-153.
96. Walker DM, Malarkey DE, Seilkop SK, Ruecker FA, Funk KA, Wolfe MJ, Treanor CP, Foley JF, Hahn FF, Hardisty JF, Walker VE. 2007. Transplacental carcinogenicity of 3′-azido-3′-deoxythymi-dine in B6C3F1 mice and F344 rats. Environ Mol Mutagen 48:283-298.
97. Walker UA, Venhoff N. 2001. Multiple mitochondrial DNA deletions and lactic acidosis in an HIV-infected patient under antiretroviral therapy. AIDS 15:1449-1450.
98. Walker VE, Poirier MC. 2007. Foreword: Special issue on health risks of perinatal exposure to nucleoside reverse transcriptase inhibitors. Environ Mol Mutagen 48:159-165.
99. Walker VE, Skopek TR. 1993. A mouse model for the study of in vivo mutational spectra: Sequence specificity of ethylene oxide at the Hprt locus. Mutat Res 288:151-162.
100. Watts DH. 2006. Treating HIV during pregnancy. An update on safety issues. Drug Safety 29:467-490.
101. Witt KL, Cunningham CK, Patterson KB, Kissling GE, Dertinger SD Livingston E, Bishop JB. 2007. Elevated frequencies of micro-nucleated erythrocytes in infants exposed to zidovudine in utero and postpartum to prevent mother-to-child transmission of HIV. Environ Mol Mutagen 48:322-329.
102. Wogan G. 2007. Does perinatal antiretroviral therapy create an iatrogenic cancer risk? Environ Mol Mutagen 48:210-214.
103. Wutzler P, Thust R. 2001. Genetic risks of antiviral nucleoside analogues-A survey. Antiviral Res 49:55-74.
104. Yoon KL, Aprille JR, Ernst SG. 1991. Mitochondrial tRNA(thr) mutation in fatal infantile respiratory enzyme deficiency. Biochem Res Commun 176:1112-1115.
105. Zaera MG, Miró Ò, Pedrol E, Soler A, Picón M, Cardellach F, Casademont J, Nunes V. 2001. Mitochondrial involvement in antiretroviral therapy-related lipodystrophy. AIDS 15:1643-1651.